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Abstract
Background: Although mitochondrial dysfunction is consistently manifested in patients with Type
2 Diabetes mellitus (T2DM), the association of mitochondrial DNA (mtDNA) sequence variants
with T2DM varies among populations. These differences might stem from differing environmental
influences among populations. However, other potentially important considerations emanate from
the very nature of mitochondrial genetics, namely the notable high degree of partitioning in the
distribution of human mtDNA variants among populations, as well as the interaction of mtDNA
and nuclear DNA-encoded factors working in concert to govern mitochondrial function. We
hypothesized that association of mtDNA genetic variants with T2DM could be revealed while
controlling for the effect of additional inherited factors, reflected in family history information.
Methods: To test this hypothesis we set out to investigate whether mtDNA genetic variants will
be differentially associated with T2DM depending on the diabetes status of the parents. To this end,
association of mtDNA genetic backgrounds (haplogroups) with T2DM was assessed in 1055 Jewish
patients with and without T2DM parents ('DP' and 'HP', respectively).
Results: Haplogroup J1 was found to be 2.4 fold under-represented in the 'HP' patients (p =
0.0035). These results are consistent with a previous observation made in Finnish T2DM patients.
Moreover, assessing the haplogroup distribution in 'DP' versus 'HP' patients having diabetic siblings
revealed that haplogroup J1 was virtually absent in the 'HP' group.
Conclusion:  These results imply the involvement of inherited factors, which modulate the
susceptibility of haplogroup J1 to T2DM.
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Background
Mitochondrial dysfunction in Type 2 diabetes (T2DM)
patients has been repeatedly reported [1], however clear
evidence for mitochondrial genetic involvement in the
disease is yet to be determined [2].
Recent studies revealed the apparent association of certain
mitochondrial DNA (mtDNA) genetic backgrounds (hap-
lotypes, haplogroups) with T2DM in Asians [3], but not in
Caucasians [4,5]. Others described the association of cer-
tain mtDNA common variants, such as the T16189C vari-
ant with T2DM in various populations [6], however, this
association was recently questioned [7]. Such apparent
discrepancies are frequently viewed as pointing to false
positive associations [8]. Nevertheless, putative function-
ality of mtDNA genetic variants could be strongly affected
by population dynamics due to the exceptionally high
genetic variability of human mtDNA, with many of the
mtDNA SNPs being population specific [9,10]. This is evi-
dent when considering the association of mtDNA haplo-
group J with longevity in the Irish, some French, and in
northern but not southern Italians [11]. Other factors that
add to the complex nature of mitochondrial genetics
involvement in multifactorial diseases include: (A) dis-
ease-associated somatic mtDNA mutations; (B) the close
interaction of mtDNA-encoded proteins with nuclear
DNA-encoded proteins [12]; and (C) the possibility that
many complex diseases, such as T2DM, constitute a mix-
ture of disease entities. Accordingly, case-control associa-
tion studies of mtDNA with T2DM as a whole might mask
intermediary disease predisposing states, yielding average
results with similar haplogroups distribution to that of a
control population [10]. This interpretation is reflected in
the lack of mtDNA haplogroups' association with T2DM
that was reported in a study of more than 6,000 healthy
and T2DM Caucasian samples [5]. Moreover, when we
compared the mtDNA haplogroup distribution that was
recently analyzed in a set of Ashkenazi Jewish T2DM
patients [10] to 565 non diabetic Ashkenazi Jewish con-
trols [13] we once again observed no significant differ-
ences in distribution of haplogroups between cases and
controls (Additional file 1: Table S1, R × C test of inde-
pendence performed on this data resulted in p = 0.1). To
overcome this difficulty, and since the heritability of
T2DM as a whole is not robust, we adopted a different
approach, namely study the association of mtDNA haplo-
groups with T2DM in a cohort divided into sub-groups,
according to the parental diabetes status, i.e. patients with
healthy parents or T2DM parents.
Methods
Patient Cohorts and mtDNA haplogroup assignment
The assembly of T2DM patients' cohorts analyzed in the
current study and the process of designating the mtDNA
genetic haplogroups were previously described [10].
Briefly, the patients are all of Jewish origin, have no
reported family connections, and were recruited in 7 dif-
ferent medical centers in Israel, following informed con-
sent and approval by local IRB and national Helsinki
medical research ethics boards. The studied cohort
encompasses three Jewish subgroups: Ashkenazi (Ash),
Sephardic (Seph) and North African Jews (NAF). The
countries of origin are as follows; Ash cohort – Germany,
Austria, Switzerland, former Czechoslovakia, Hungary,
Yugoslavia, United Kingdom, Ireland, Poland, USA, Can-
ada, Holland, Argentina, Ukraine, Russia, Latvia, Lithua-
nia and Romania; Seph cohort – Cyprus, Bulgaria, Greece,
Spain, Italy and Turkey; NAF cohort – Morocco, Algeria,
Tunisia, Libya and Egypt. If the patient's country of origin
was 'Israel', the patients' declared ethnicity was assigned
(Ash, Seph or NAF). MtDNA haplogroup analysis was per-
formed by RFLP of selected mtDNA polymorphic sites
and partial sequence of the hypervariable region 1 of the
mtDNA as described previously [10]. Out of the 1179
patients comprising our formerly studied cohort [10], we
currently focused on 1055 patients having sufficient fam-
ily history information. This information originated from
questionnaires completed by the patients themselves,
providing direct answers to questions about health
parameters and specifically the T2DM status of each of the
parents, siblings and descendants.
Permutation test
In order to detect candidate mtDNA haplogroups in
which the parental diabetic status of the patients is
altered, we used permutation tests. These tests were per-
formed using MATLAB (v.6.5) script: The parental dia-
betic status (a binary indicator variable, 0 – healthy
parents and 1-parents with T2DM) was randomly
assigned to patients with known haplogroups. Next, the
proportion of patients in each haplogroup who have a
diabetic parent was calculated, and the absolute difference
(two-tailed test) between each of these values and the
overall proportion of patients having a diabetic parent
(i.e., the proportion of patients with at least one diabetic
parent irrespective of their genetic background) was
recorded. This procedure was repeated 10,000 times. P-
values were estimated as the proportion of cases in which
the absolute difference obtained during the permutations
was equal to or greater than that found in the original
dataset. The same procedure was performed to detect can-
didate haplogroups among patients further divided into
(1) patients having at least one T2DM sibling and (2)
patients with healthy siblings.
Log linear model analysis and model selection procedure
Since our dataset include only categorical/strata variables we
adopted a statistical method that allows analyzing contin-
gency tables or frequencies of occurrence. Specifically, we
used a Log-Linear Model analysis to assess the relationship
between mtDNA haplogroups of the patients and the T2DM
status of their parents (healthy vs. T2DM parents), with theBMC Medical Genetics 2009, 10:60 http://www.biomedcentral.com/1471-2350/10/60
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T2DM parents further divided into T2DM mother only,
T2DM father only and T2DM mother and father. We also
took into account the T2DM status of the siblings, as well as
geographic origin of each Jewish population.
As accepted in Log Linear analysis, higher-order interac-
tion terms were examined first. The derived lower-order
interaction terms were excluded since they are already
included in the former. All examined models included the
effects of the four main components outlined above.
According to this logic, we first examined the four-way-
interaction term model, followed by the models harbor-
ing different combinations of three- and two-way-interac-
tion terms. The model best fitting our data was chosen
using a model selection procedure [14]. Briefly, the model
with the lowest Akaike Information Criterion (AIC) was
considered as a reference model best explaining the data
with a minimum of free parameters, and the rest were
evaluated based on their AIC deviation (ΔAIC) from that
model. Because AIC is a comparative index, only relative
values are relevant. For log linear models, a relative AIC
value, scaled so that AIC for the saturated model is zero, is
given by AIC = G2 - 2*(DF) where G2 is the best-fit likeli-
hood ratio statistic, testing the model against the saturated
model, and DF is its degrees of freedom [15]. Both values
(G2, DF) are reported by standard statistical software
packages. As accepted in such an analysis, only the refer-
ence model as well as models with ΔAIC ≤ 2 were consid-
ered for further investigation [14]. Similar results were
obtained both when we started with a saturated model
harboring all possible interaction terms or when testing
the contribution of each interaction to the overall signifi-
cance by hierarchically removing different combinations
of the tested components [16]. In this case, changes in G
(ΔG values) were used to evaluate the significance of the
different parameters or combinations that were removed
from the model.
Results
In order to test whether parental T2DM status influences
the association of mtDNA haplogroups with T2DM, we
compared the distribution of mtDNA haplogroups in
T2DM patients that have either healthy or T2DM parents.
This information was provided by the patients in response
to a questionnaire (Methods section).
To this end, we first determined the mtDNA genetic back-
grounds of 1055 T2DM patients of Jewish origin (661
Ashkenazi Jews [Ash] and 394 non-Ashkenazi Jews, com-
prising Sephardic [Seph] and North African Jews [NAF]),
revealing that ~90% of the subjects belonged to one of the
12 most prevalent mtDNA haplogroups in Ashkenazi
Jews, i.e., K1, K2, U (non-K), H, V, J1, J2, T, N1b, I, X, W.
This cohort is a subset of a cohort of patients that we pre-
viously studied [10] (see Materials and Methods section).
Since the family history (including T2DM history of par-
ents and siblings) and information regarding the geo-
graphic/ethnic origin was available for the subjects,
patients were divided into the following: (A) a group with
at least one diabetic parent (designated 'DP', further
divided into three subgroups -only diabetic mother, only
diabetic father and both diabetic parents) and (B) a group
of patients of whom neither of the parents had T2DM
(designated 'HP' e.g., healthy parents).
To avoid multiple testing we first identified candidate
haplogroups for association with T2DM in the context of
the parental health status using a permutation test. This
analysis yielded a significant 2.4 fold under-representa-
tion of haplogroup J1 in the 'HP' versus 'DP' groups of
patients (13/369, 3.5% in the 'HP' versus 57/686, 8.3% in
the 'DP' group, p = 0.0035, Table 1). Such a significant dif-
ference was not observed in any other tested haplogroups.
The observed 2.4 fold under-representation of haplo-
group J1 in the 'HP' versus 'DP' groups of patients was also
evident after dividing the total Jewish sample into
Ashkenazi (Additional file 1: Table S2) and the smaller
sub-group of non-Ashkenazi patients (Additional file 1:
Table S3). Hence haplogroup J1 was selected as a candi-
date haplogroup for further investigation.
To further decipher whether haplogroup J1 altered the
susceptibility to T2DM depending on an additional factor
and whether this added component is indeed inherited, a
Log Linear Model analysis [16] was conducted (Table 2).
We chose this approach as it offers a single test to assess
the interaction of several factors that could affect the asso-
ciation of haplogroup J1 with T2DM, thus avoiding mul-
tiple consecutive tests. Specifically, this analysis tested
interactions between the patients' genetic background and
their T2DM family history, including the T2DM parental
status, the existence of T2DM siblings and the geographic
origin of the patients. These parameters were designated
as J1 (patients assigned to haplogroup J1 versus patients
pertaining to all other haplogroups in the aggregate); I
('HP' vs. 'DP' patients, with the latter further divided into
three subgroups -only diabetic mother, only diabetic
father and both diabetic parents); S (patients with at least
one T2DM sibling vs. patients with no T2DM siblings)
and P (population-of-origin including ASH, SEPH and
NAF, noting differences in mtDNA genetic landscape
among different Jewish populations, [10,17-20]).
Using a model selection procedure [14] we found that the
model best fitting our data included the following four
two-way-interaction terms: J1 × I; J1 × P; I × S; S × P (Table
2, model #11). This model indicates that even after taking
into account the significant under-representation of hap-
logroup J1 in the NAF population (J1 × P interaction term;
ΔG = 7.99, DF = 2, p = 0.018) (Additional file 1: Table S4),BMC Medical Genetics 2009, 10:60 http://www.biomedcentral.com/1471-2350/10/60
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and the significant variation in the number of patients
with at least one T2DM sibling among the different popu-
lations (S × P interaction term; ΔG = 48.98, DF = 2, p <
0.001), there remains a significant interaction between
haplogroup J1 and the parental T2DM status (J1 × I inter-
action term; ΔG = 12.23, DF = 3, p = 0.007). As expected,
the analysis also indicated a significant interaction
between the parental T2DM status and that of the T2DM
siblings (I × S interaction term; ΔG = 30.44, DF = 3, p <
0.001).
The above findings further indicate that the association of
haplogroup J1 with T2DM markedly depends on the
T2DM status of the parents of the diabetic subjects. To
substantiate this information we assessed the association
of haplogroup J1 with the T2DM status of the patients'
siblings. This was performed based on the assumption
that mtDNA is maternally inherited and therefore all bio-
logical siblings of a given patient will carry the same
mtDNA genetic background. Therefore, the T2DM history
of the patient's siblings could substantiate the depend-
ency of haplogroup J1 association with the parental dis-
ease-status. Since T2DM is an age-related disease and
because the average age of our T2DM patients was 55
years old, only siblings of age above 54 years were
included in the analysis. Moreover, the distribution of the
number of siblings above 54 years of age was consistent
among haplogroups (J1 vs. the aggregate of all other hap-
logroups) and between the 'DP' and 'HP' patient groups
(G = 2.799, DF = 5, p = 0.731; and G = 8.038, DF = 5, p =
0.154, respectively). Thus, we could divide our patient
group into patients with at least one T2DM sibling and
patients with healthy siblings. This division significantly
emphasized the under-representation of haplogroup J1 in
the 'HP' patients as was clearly evident in our statistical
analysis (J1 × I interaction term; ΔG = 12.23, DF = 3, p =
0.007; Table 2). Furthermore, haplogroup J1 was virtually
absent among 'HP' patients with T2DM siblings (1/88,
1.1%), but retained its proportion in the 'DP' patients
with at least one T2DM sibling (23/279, 8.2%, p = 0.022)
(Table 3). Notably, the percentages of patients with at
least one T2DM sibling remained unaltered among the
Table 1: Permutation test of haplogroup distribution among patients with T2DM parents (designated 'DP') versus patients with 
healthy parents (designated 'HP'). 
Haplogroup 'HP' Patients 'DP' Patients P value (permutation test) Total patients 'DP'/Total
H 87 (23.6%) 172 (25.1%) 0.604 259 0.664093
HV 38 (10.3%) 75 (10.9%) 0.7496 113 0.663717
J1 13 (3.5%) 57 (8.3%) 0.0035 70 0.814286
J2 7 (1.9%) 4 (0.6%) 0.0556 11 0.363636
K1 84 (22.8%) 122 (17.8%) 0.0608 206 0.592233
K2 17 (4.6%) 25 (3.6%) 0.5141 42 0.595238
N1b 21 (5.7%) 22 (3.2%) 0.0699 43 0.511628
Other 40 (10.8%) 76 (11.1%) 0.9203 116 0.655172
T 17 (4.6%) 40 (5.8%) 0.4726 57 0.701754
U 26 (7%) 51 (7.4%) 0.9025 77 0.662338
WXI 19 (5.1%) 42 (6.1%) 0.5807 61 0.688525
Total 369 686 1055
Numbers in parentheses: percentage of the total sample size in each column.
Table 2: A log linear model analysis testing for the relationship between mtDNA genetic background (haplogroup J1 versus all other 
haplogroups in the aggregate), T2DM status of the parents (I), T2DM status of the siblings (S) and population-of-origin (P).
Model No. Model G2 Degrees of Freedom Akaike Information Criterion (AIC)* ΔAIC
1 J1 × I × S × P 72.7317 34 4.7317 43.0524
2 J1 × I × S; J1 × I × P; J1 × S × P; I × S × P 35.8467 23 -10.1533 28.1674
3 J1 × I × S; J1 × I × P; J1 × S × P 44.1794 29 -13.8206 24.5001
4 J1 × I × S; J1 × S × P 60.9351 35 -9.0649 29.2558
5 J1 × S × P 86.7039 38 10.7039 49.0246
6 J1 × S × P; J1 × I; S × I 44.1896 32 -19.8104 18.5103
7 J1 × I × S; S × P 47.2893 35 -22.7107 15.61
8 J1 × I × P; I × S; S × P 26.3029 29 -31.6971 6.6236
9 I × S × P; J1 × I 88.7164 31 26.7164 65.0371
10 J1 × I; J1 × S; J1 × P; I × S; I × P; S × P 21.1262 23 -24.8738 13.4469
11 J1 × I; J1 × P; I × S; S × P 21.6793 30 -38.3207 0
12 J1 × I; S × P; I × S 29.6666 32 -34.3334 3.9873BMC Medical Genetics 2009, 10:60 http://www.biomedcentral.com/1471-2350/10/60
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'HP' and 'DP' T2DM patients pertaining to all other hap-
logroups. When the same analysis was performed in
patients with healthy siblings, J1 was under-represented
to the same extent as evident in the entire cohort. This sug-
gests that the T2DM status of the parents carries a modify-
ing effect of haplogroup J1 association with T2DM. It is
important to note that although T2DM siblings appear to
enhance the association of J1 with T2DM family history,
the "sibling" component failed to produce a significant
interaction with J1 on its own (Table 2). We interpret this
as the "sibling" factor in our analysis being a dependent
component of the T2DM parental status, as intuitively
could be expected from the fact that the same mtDNA is
transferred to all of the siblings; thus, its effect could be
revealed only when combined with the parental T2DM
status, further supporting the interaction of T2DM family
history with haplogroup J1. Taken together, our approach
proved successful in demonstrating a significant mito-
chondrial genetic contribution to T2DM, which hereto-
fore has been difficult to tease out from among the
multiple factors contributing to T2DM disease predisposi-
tion.
Discussion
MtDNA association with T2DM has been described in
Asians but was questioned in Caucasians. We hypothe-
sized, that apart from the evident environmental differ-
ences, such inconsistency could reflect either of two
alternatives: (A) mtDNA has little or no genetic contribu-
tion to T2DM in Caucasians or (B) mtDNA contribution
to T2DM involves additional genetic factors, the contribu-
tion of which is more prominent in Caucasians, thus
masking its association. We aimed to test the second pos-
sibility by investigating the distribution of mtDNA haplo-
groups in a large Jewish T2DM patient cohort taking into
account the T2DM status of the patients' parents, thus
controlling for the involvement of additional putative
genetic factors. By using the Log Linear Model and model
selection approach we were able to test for possible asso-
ciation of mtDNA haplogroups with T2DM taking into
account not only the diabetes status of the parents as well
as their siblings, but also controlling for the geographic
origin of the studied populations in a single test. Our
approach revealed an association of haplogroup J1 with
T2DM depending on the diabetes status of the parents.
Most importantly, the fact that the three way interaction
term J1 × I × P was not included in the emerging model
indicated that the under-representation of haplogroup J1
in the 'HP' versus 'DP' groups of patients was consistent
among the studied Jewish populations. This result implies
that the interaction J1 × I might be applicable to popula-
tions other than Jews. Indeed, Mohlke et al previously
reported an association of haplogroup J with T2DM in
Finns while controlling for the parental diabetes status
[4]. Thus, our careful control for family history informa-
tion unearthed the association of mtDNA variants with
T2DM, as was suggested for a non-Jewish population, sup-
porting possible application of our approach to other
populations of Caucasian ancestry.
A maternal bias towards the inheritance of T2DM has
been debated [21,22]. Therefore, in our Log Linear Model,
we divided the group of 'DP' patients into three subgroups
– patients with T2DM mother only, patients with T2DM
father only and patients with both T2DM parents. Within
the 'DP' patients as a whole, the proportion of T2DM
mothers exceeded by 3 fold that of T2DM fathers. How-
ever, this pattern was consistent in all patients, either per-
taining to haplogroup J1 or non-J1 (38/57, 66.7% and
365/628, 58.1%, respectively), implying that there was lit-
tle or no differential contribution of the parental gender
to the altered distribution of J1 haplogroup in our patient
cohort. In other words, the frequency of haplogroup J1
varied between 'HP' and 'DP' patients, rather than among
the three 'DP' subgroups, resulting in a significant J1 × I
interaction term. This implies that the modulating factor
Table 3: Permutation test of haplogroup distribution in 'HP' and 'DP' patients with at least one T2DM sibling. 
Haplogroup 'HP' patients with 
T2DM sibs
'DP' patients with 
T2DM sibs
P value 
(permutation test)
Total number of 
patients
'DP'/Total
H 19 (21.6%) 73 (26.2%) 0.3997 92 0.793478
HV 13 (14.8%) 34 (12.2%) 0.5837 47 0.723404
J1 1 (1.1%) 23 (8.2%) 0.0228 24 0.958333
J2 2 (2.3%) 2 (0.7%) 0.246 4 0.5
K1 19 (21.5%) 39 (13.97%) 0.095 58 0.672414
K2 4 (4.5%) 15 (5.4%) 0.7962 19 0.789474
N1b 4 (4.5%) 9 (3.2%) 0.7448 13 0.692308
Other 8 (9.1%) 32 (11.5%) 0.5695 40 0.8
T 3 (3.4%) 14 (5%) 0.5842 17 0.823529
U 7 (7.9%) 21 (7.5%) 1 28 0.75
WXI 8 (9.1%) 17 (6.1%) 0.3475 25 0.68
Total 88 279 367
Numbers in parenthesis: percentage of the total sample size in each column.BMC Medical Genetics 2009, 10:60 http://www.biomedcentral.com/1471-2350/10/60
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of haplogroup J1 association with T2DM is not necessarily
maternally inherited.
Haplogroup J was previously associated with reduced ten-
dency of certain Caucasian populations to develop Par-
kinson's disease [23] and with successful longevity [24].
Its sub-group J1 increases the penetrance of Leber's Hered-
itary Optic Neuropathy mutations, and recently was
found by us to increase the susceptibility of Ashkenazi
T2DM patients to develop certain complications [10].
This suggests that mutations defining this haplogroup
likely have mitochondrial functional consequences. Our
current association of haplogroup J1 with T2DM in Jews
further underlines the phenotypic impact of this mtDNA
genetic background.
Taken together our results suggest that haplogroup J1
alters the susceptibility to T2DM, depending on the paren-
tal health condition. This implies the existence of an
inherited factor, which modulates haplogroup J1 associa-
tion with T2DM. This very effect was more prominent
when taking into account the siblings' T2DM status. A
recent study that focused on certain mtDNA variants using
Indian populations implied that certain combinations of
nuclear and mitochondrial encoded variants, especially in
regulatory factors of mitochondrial biogenesis, can
increase the susceptibility to T2DM, thus supporting our
interpretation [12]. Moreover, the synergistic effect of
nuclear-mitochondrial genetic variants on disease suscep-
tibility was shown in other disorders as well [25]. Thus,
mitochondrial genetic association with complex diseases
almost certainly involves the interaction of nuclear and
mtDNA-encoded factors.
Conclusion
Several lines of evidence have emerged from our findings,
all stem from the use of a suitable approach to identify
association of mtDNA haplogroups with T2DM in Cauca-
sian (Jewish) patients:
1. Our approach employs a comparison between two sub-
groups within a large heterogeneous Jewish cohort of
T2DM patients classified according to the diabetes status
of their parents. Similar to our previous report [10], the
current analysis suggests that, rather than comparing the
entire cohort of diabetic patients to healthy individuals, a
comparison of subgroups within the diabetic population
is more meaningful. This is because it enables focusing on
distinct phenotypes within the heterogenic spectrum of
the diabetic syndrome, thus providing an approach to sort
mtDNA variants' association with T2DM from the 'noise'.
2. Our comparisons yielded a significant association of
mtDNA haplogroup J1 with T2DM depending on the
parental diabetes status. More specifically, haplogroup J1
was notably under-represented in T2DM patients with
healthy parents, as compared to patients with T2DM par-
ents. The interpreted under presentation of haplogroup J1
in the HP patients is in light of the fact that the prevalence
of haplogroup J1 in the general Ashkenazi Jewish popula-
tion was similar to the DP patients. Apparently, it seems
that the penetrance of the phenotypic effect of mtDNA
variants is differentially modified by parentally inherited
factors. Since such modifying factors were not taken into
account in previous mtDNA association studies with
T2DM, they could provide a possible explanation why
past comparisons of mtDNA variation between Caucasian
T2DM patients and controls failed to yield clear associa-
tion.
3. Our approach succeeded in detecting the existence of an
inherited component, which affected the association of
mtDNA haplogroup J1 with T2DM in Caucasians. Detect-
ing the effect of such a component became feasible by uti-
lizing the Log Linear model and model selection
approach, which controlled for the geographic origin of
the patients, thus ruling out the involvement of popula-
tion sub-structure in the observed association. In addi-
tion, this approach allowed in a single test to assess
whether any of the multiple parameters (geographic ori-
gin of the patients, the existence of T2DM siblings and
parental sex) affect the association while avoiding multi-
ple testing.
4. Our model selection method showed that the observed
association depended on the diabetes status of the parents
regardless of their sex. This implies the existence of modi-
fying factor/s for the phenotypic effect of haplogroup J1
that is inherited either from the father or the mother, and
is therefore most plausibly located in the nuclear genome.
In summary our discovered association of mtDNA vari-
ants with T2DM in Caucasians support our approach and
suggest that during mtDNA association studies the
involvement of other genetic factors should be controlled
for.
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